BACKGROUND: While transfemoral (TF) approach is considered as the default access for transcatheter aortic valve replacement (TAVR), the alternative access route of choice remains to be elucidated. Transaxillary (TAx) approach has shown promise as an excellent option. We performed a meta-analysis of the studies comparing the TF and TAx approaches using one type of self-expandable transcatheter valve to avoid device-related bias. METHODS: We searched PubMed/MEDLINE, EMBASE, and the Cochrane Library from inception to December 2018 to identify articles comparing TAx-TAVR and TF-TAVR. The studies included in this meta-analysis contain data related to the use of the CoreValve device. Patients' baseline characteristics, procedural outcomes, and clinical outcomes were extracted from the articles and pooled for analysis. RESULTS: The meta-analysis included five studies comprising 1,414 patients in the TF group and 489 patients in the TAx group. The average EuroScores of the TF and TAx groups were 20.04±13.89 and 22.73±14.73, respectively. The TAx group has higher rates of major comorbidities. No difference was found between the two groups with regard to vascular complications (P=0.71; OR 1.08; 95% CI, 0.71-1.65), aortic regurgitation (P=0.90; OR 1.03; 95% CI, 0.71-1.49), and permanent pacemaker (PPM) implantation (P=0.42; OR 1.12; 95% CI, 0.86-1.46). The TAx group has a lower incidence of acute kidney injury (AKI) (P=0.05; OR 1.63; 95% CI, 1.01-2.62). No difference was observed in 30-day mortality (P=0.32; OR 1.30; 95% CI, 0.78-2.17) or 1-year mortality (P=0.21; OR 0.76; 95% CI, 0.50-1.16). CONCLUSIONS: TAx-TAVR is associated with overall comparable outcomes to TF TAVR in high-risk patient cohorts, despite higher incidences of major comorbidities in the TAx-TAVR patient population. The rate of AKI appears to be lower after TAx-TAVR. 2019 Journal of Thoracic Disease. All rights reserved.
BACKGROUND: While transfemoral (TF) approach is considered as the default access for transcatheter aortic valve replacement (TAVR), the alternative access route of choice remains to be elucidated. Transaxillary (TAx) approach has shown promise as an excellent option. We performed a meta-analysis of the studies comparing the TF and TAx approaches using one type of self-expandable transcatheter valve to avoid device-related bias. METHODS: We searched PubMed/MEDLINE, EMBASE, and the Cochrane Library from inception to December 2018 to identify articles comparing TAx-TAVR and TF-TAVR. The studies included in this meta-analysis contain data related to the use of the CoreValve device. Patients' baseline characteristics, procedural outcomes, and clinical outcomes were extracted from the articles and pooled for analysis. RESULTS: The meta-analysis included five studies comprising 1,414 patients in the TF group and 489 patients in the TAx group. The average EuroScores of the TF and TAx groups were 20.04±13.89 and 22.73±14.73, respectively. The TAx group has higher rates of major comorbidities. No difference was found between the two groups with regard to vascular complications (P=0.71; OR 1.08; 95% CI, 0.71-1.65), aortic regurgitation (P=0.90; OR 1.03; 95% CI, 0.71-1.49), and permanent pacemaker (PPM) implantation (P=0.42; OR 1.12; 95% CI, 0.86-1.46). The TAx group has a lower incidence of acute kidney injury (AKI) (P=0.05; OR 1.63; 95% CI, 1.01-2.62). No difference was observed in 30-day mortality (P=0.32; OR 1.30; 95% CI, 0.78-2.17) or 1-year mortality (P=0.21; OR 0.76; 95% CI, 0.50-1.16). CONCLUSIONS: TAx-TAVR is associated with overall comparable outcomes to TF TAVR in high-risk patient cohorts, despite higher incidences of major comorbidities in the TAx-TAVR patient population. The rate of AKI appears to be lower after TAx-TAVR. 2019 Journal of Thoracic Disease. All rights reserved.
Authors: Anna Sonia Petronio; Marco De Carlo; Francesco Bedogni; Francesco Maisano; Federica Ettori; Silvio Klugmann; Arnaldo Poli; Antonio Marzocchi; Gennaro Santoro; Massimo Napodano; Gian Paolo Ussia; Cristina Giannini; Nedy Brambilla; Antonio Colombo Journal: J Am Coll Cardiol Date: 2012-06-20 Impact factor: 24.094
Authors: Kees van der Wulp; Michel W A Verkroost; Marleen H van Wely; Helmut R Gehlmann; Leen A F M Van Garsse; L Noyez; Marc A Brouwer; Peter C Kievit; Menko-Jan De Boer; Harry Suryapranata; Wim J Morshuis; Niels van Royen Journal: Ann Thorac Surg Date: 2018-10-04 Impact factor: 4.330
Authors: Michael J Mack; Martin B Leon; Vinod H Thourani; Raj Makkar; Susheel K Kodali; Mark Russo; Samir R Kapadia; S Chris Malaisrie; David J Cohen; Philippe Pibarot; Jonathon Leipsic; Rebecca T Hahn; Philipp Blanke; Mathew R Williams; James M McCabe; David L Brown; Vasilis Babaliaros; Scott Goldman; Wilson Y Szeto; Philippe Genereux; Ashish Pershad; Stuart J Pocock; Maria C Alu; John G Webb; Craig R Smith Journal: N Engl J Med Date: 2019-03-16 Impact factor: 91.245
Authors: Daniel C Garcia; Alexandre Benjo; Rhanderson N Cardoso; Francisco Yuri B Macedo; Patricia Chavez; Emad F Aziz; Eyal Herzog; Mahboob Alam; Eduardo de Marchena Journal: Int J Cardiol Date: 2014-01-09 Impact factor: 4.164
Authors: Martine Gilard; Hélène Eltchaninoff; Bernard Iung; Patrick Donzeau-Gouge; Karine Chevreul; Jean Fajadet; Pascal Leprince; Alain Leguerrier; Michel Lievre; Alain Prat; Emmanuel Teiger; Thierry Lefevre; Dominique Himbert; Didier Tchetche; Didier Carrié; Bernard Albat; Alain Cribier; Gilles Rioufol; Arnaud Sudre; Didier Blanchard; Frederic Collet; Pierre Dos Santos; Nicolas Meneveau; Ashok Tirouvanziam; Christophe Caussin; Philippe Guyon; Jacques Boschat; Herve Le Breton; Frederic Collart; Remi Houel; Stephane Delpine; Geraud Souteyrand; Xavier Favereau; Patrick Ohlmann; Vincent Doisy; Gilles Grollier; Antoine Gommeaux; Jean-Philippe Claudel; Francois Bourlon; Bernard Bertrand; Eric Van Belle; Marc Laskar Journal: N Engl J Med Date: 2012-05-03 Impact factor: 91.245
Authors: Cosmo Godino; Francesco Maisano; Matteo Montorfano; Azeem Latib; Alaide Chieffo; Iassen Michev; Rasha Al-Lamee; Marta Bande; Marco Mussardo; Francesco Arioli; Alfonso Ielasi; Micaela Cioni; Maurizio Taramasso; Irina Arendar; Antonio Grimaldi; Pietro Spagnolo; Alberto Zangrillo; Giovanni La Canna; Ottavio Alfieri; Antonio Colombo Journal: JACC Cardiovasc Interv Date: 2010-11 Impact factor: 11.195
Authors: Nicholas Aroney; Tiffany Patterson; Christopher Allen; Simon Redwood; Bernard Prendergast Journal: J Clin Med Date: 2021-04-20 Impact factor: 4.241